Testavan 20 mg/ g Norge - norsk - Statens legemiddelverk

testavan 20 mg/ g

the simple pharma company limited - testosteron - transdermalgel - 20 mg/ g

Testogel 50 mg/5 g Norge - norsk - Statens legemiddelverk

testogel 50 mg/5 g

laboratoires besins international - testosteron - transdermalgel i dosepose - 50 mg/5 g

Tostran 2 % Norge - norsk - Statens legemiddelverk

tostran 2 %

kyowa kirin holdings b.v. - testosteron - gel - 2 %

Intrinsa Den europeiske union - norsk - EMA (European Medicines Agency)

intrinsa

warner chilcott uk ltd. - testosteron - seksuelle dysfunksjoner, psykologisk - sex hormoner og modulatorer av genital systemet, - intrinsa er indisert for behandling av hypoactive seksuell lyst lidelse (hsdd) i bilateralt oophorectomised og hysterectomised (kirurgisk indusert overgangsalder) kvinner mottar samtidig estrogen terapi.

Livensa Den europeiske union - norsk - EMA (European Medicines Agency)

livensa

warner chilcott  deutschland gmbh - testosteron - seksuelle dysfunksjoner, psykologisk - sex hormoner og modulatorer av genital systemet, - livensa er indisert for behandling av hypoactive seksuell lyst lidelse (hsdd) i bilateralt oophorectomised og hysterectomised (kirurgisk indusert overgangsalder) kvinner mottar samtidig estrogen terapi.

Nebido 1000 mg/4 ml Norge - norsk - Statens legemiddelverk

nebido 1000 mg/4 ml

grünenthal gmbh - testosteronundekanoat - injeksjonsvæske, oppløsning - 1000 mg/4 ml

Testosteronundekanoat Medical Valley 1000 mg/4 ml Norge - norsk - Statens legemiddelverk

testosteronundekanoat medical valley 1000 mg/4 ml

medical valley invest ab - testosteronundekanoat - injeksjonsvæske, oppløsning - 1000 mg/4 ml

Leuprorelin Sandoz 5 mg Norge - norsk - Statens legemiddelverk

leuprorelin sandoz 5 mg

sandoz - københavn - leuprorelinacetat - implantat - 5 mg

Firmagon Den europeiske union - norsk - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degarelix - prostata neoplasmer - endokrin terapi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Degarelix Accord Den europeiske union - norsk - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prostata neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.